CX-2029 is a conditionally activated antibody-drug conjugate (Probody® therapeutic) employing the MMAE payload and targeting CD71, also known as the transferrin receptor 1. CX-2029 has a peptide-mask that is held in place by a protease-cleavable linker. Protease activation is tightly controlled in normal tissues but often poorly regulated in tumor tissues leading to abundant levels of activated proteases.
CX-2029 is currently being evaluated in a multi-cohort Phase 2 dose expansion study as monotherapy in patients with squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal or gastroesophageal junction cancer, or diffuse large B-cell lymphoma. CX-2029 is being developed in partnership with AbbVie.
Purpose: The purpose of this first-in-human study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics and antitumor activity of CX-2029 in patients with one of four metastatic or locally advanced tumors.
If you are interested in learning more about this study including participating sites, please visit clinicaltrials.gov.